<DOC>
	<DOCNO>NCT02783430</DOCNO>
	<brief_summary>KetaPal placebo-controlled randomized trial design demonstrate antidepressant action ketamine palliative care situation . Half participant receive Ketamine Milnacipran combination , half receive Placebo Milnacipran combination .</brief_summary>
	<brief_title>Evaluation Initial Prescription Ketamine Milnacipran Depression Palliative Care</brief_title>
	<detailed_description>Ketamine , molecule mainly use analgesic palliative care , turn excellent fast act antidepressant . By act NMDA receptor antagonist , mechanism action complementary classical long act antidepressant like Selective Serotonin Reuptake Inhibitors ( SSRI ) . In particular , ketamine able boost synaptogenesis hour whereas long-term prescription SSRI stimulate neurogenesis . The purpose study evaluate new therapeutic strategy could integrate ketamine time SSRI , control depression symptom faster optimize patient 's quality life complementary treatment cancer .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Inpatient Supported functional palliative care unit Having severe progressive disease diagnose Meet criterion major depressive disorder define DSM version 5 MADRS &gt; 19 ( moderate severe ) No antidepressant treatment treatment introduce four week In ability receive clear information give consent Beneficiary social security scheme upper weight equal 100 kg ultimate phase ( 24 72 hour prior death ) unstable patient cardiovascular disease , include uncontrolled hypertension severe renal impairment ( renal clearance le 15 ml / min ) psychiatric comorbidity : schizophrenia schizoaffective disorder neurological comorbidity : recent cerebrovascular accident ( Less one month ) , Parkinson 's disease , dementia treatment ketamine receive four week precede inclusion impaired judgment , cognitive massive sensory impairment allow receive clear information oral antidepressant treatment introduce less four week ago dosage oral antidepressant treatment upper marketing authorization four week patient cover social security system refusal sign consent minor patient guardianship pregnant woman ( implementation urine pregnancy test inclusion woman childbearing age ) lactate woman intolerance allergic reaction ketamine milnacipran . contraindication association ketamine milnacipran patient 's usual treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Palliative care</keyword>
	<keyword>Supportive care</keyword>
	<keyword>Early palliative care</keyword>
	<keyword>Fast acting antidepressant</keyword>
	<keyword>End life care</keyword>
	<keyword>Cancer</keyword>
	<keyword>psychological distress</keyword>
	<keyword>antidepressant</keyword>
	<keyword>serotonin norepinephrine reuptake inhibitor</keyword>
</DOC>